nct_id,ctgov_group_code,arm_name_ae,same_name_as_baseline,name_baseline,adverse_event_term,frequency_threshold,default_vocab,subjects_affected,subjects_at_risk,description
NCT00149227,E1,Valsartan,TRUE,Valsartan,"Total, serious adverse events",0,,0,1517,"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ï¬‚exible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."
NCT00149227,E1,Valsartan,TRUE,Valsartan,"Total, other adverse events",5,,0,1517,"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ï¬‚exible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."
NCT00149227,E2,Non-ARB,TRUE,Non-ARB,"Total, serious adverse events",0,,0,1514,"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."
NCT00149227,E2,Non-ARB,TRUE,Non-ARB,"Total, other adverse events",5,,0,1514,"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."
NCT00219141,E1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, serious adverse events",0,MedDRA,10,154,Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks.
NCT00219141,E1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, other adverse events",5,MedDRA,31,154,Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks.
NCT00219141,E2,Losartan 100 mg,TRUE,Losartan 100 mg,"Total, serious adverse events",0,MedDRA,13,152,Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks.
NCT00219141,E2,Losartan 100 mg,TRUE,Losartan 100 mg,"Total, other adverse events",5,MedDRA,31,152,Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks.
NCT00219141,E3,Aliskiren/Losartan 300/100 mg,TRUE,Aliskiren/Losartan 300/100 mg,"Total, serious adverse events",0,MedDRA,10,154,Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks.
NCT00219141,E3,Aliskiren/Losartan 300/100 mg,TRUE,Aliskiren/Losartan 300/100 mg,"Total, other adverse events",5,MedDRA,29,154,Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks.
NCT00281580,E1,PLACEBO,FALSE,,"Total, serious adverse events",0,MedDRA 10.0,0,46,
NCT00281580,E1,PLACEBO,FALSE,,"Total, other adverse events",5,MedDRA 10.0,6,NA,
NCT00281580,E10,Telmisartan 80 mg (T80),TRUE,Telmisartan 80 mg (T80),"Total, serious adverse events",0,MedDRA 10.0,1,135,
NCT00281580,E10,Telmisartan 80 mg (T80),TRUE,Telmisartan 80 mg (T80),"Total, other adverse events",5,MedDRA 10.0,5,NA,
NCT00281580,E11,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),TRUE,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),"Total, serious adverse events",0,MedDRA 10.0,2,48,
NCT00281580,E11,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),TRUE,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),"Total, other adverse events",5,MedDRA 10.0,1,NA,
NCT00281580,E12,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),TRUE,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),"Total, serious adverse events",0,MedDRA 10.0,2,146,
NCT00281580,E12,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),TRUE,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),"Total, other adverse events",5,MedDRA 10.0,10,NA,
NCT00281580,E13,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),TRUE,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),"Total, serious adverse events",0,MedDRA 10.0,0,142,
NCT00281580,E13,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),TRUE,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),"Total, other adverse events",5,MedDRA 10.0,23,NA,
NCT00281580,E14,Amlodipine 2.5 mg (A2.5),TRUE,Amlodipine 2.5 mg (A2.5),"Total, serious adverse events",0,MedDRA 10.0,1,50,
NCT00281580,E14,Amlodipine 2.5 mg (A2.5),TRUE,Amlodipine 2.5 mg (A2.5),"Total, other adverse events",5,MedDRA 10.0,2,NA,
NCT00281580,E15,Amlodipine 5 mg (A5),TRUE,Amlodipine 5 mg (A5),"Total, serious adverse events",0,MedDRA 10.0,1,140,
NCT00281580,E15,Amlodipine 5 mg (A5),TRUE,Amlodipine 5 mg (A5),"Total, other adverse events",5,MedDRA 10.0,10,NA,
NCT00281580,E16,Amlodipine 10 mg (A10),TRUE,Amlodipine 10 mg (A10),"Total, serious adverse events",0,MedDRA 10.0,0,129,
NCT00281580,E16,Amlodipine 10 mg (A10),TRUE,Amlodipine 10 mg (A10),"Total, other adverse events",5,MedDRA 10.0,29,NA,
NCT00281580,E2,Telmisartan 20 mg (T20),TRUE,Telmisartan 20 mg (T20),"Total, serious adverse events",0,MedDRA 10.0,0,42,
NCT00281580,E2,Telmisartan 20 mg (T20),TRUE,Telmisartan 20 mg (T20),"Total, other adverse events",5,MedDRA 10.0,5,NA,
NCT00281580,E3,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),TRUE,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),"Total, serious adverse events",0,MedDRA 10.0,0,44,
NCT00281580,E3,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),TRUE,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),"Total, other adverse events",5,MedDRA 10.0,4,NA,
NCT00281580,E4,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),TRUE,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),"Total, serious adverse events",0,MedDRA 10.0,0,46,
NCT00281580,E4,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),TRUE,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),"Total, other adverse events",5,MedDRA 10.0,5,NA,
NCT00281580,E5,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),TRUE,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),"Total, serious adverse events",0,MedDRA 10.0,0,44,
NCT00281580,E5,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),TRUE,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),"Total, other adverse events",5,MedDRA 10.0,6,NA,
NCT00281580,E6,Telmisartan 40 mg (T40),TRUE,Telmisartan 40 mg (T40),"Total, serious adverse events",0,MedDRA 10.0,0,130,
NCT00281580,E6,Telmisartan 40 mg (T40),TRUE,Telmisartan 40 mg (T40),"Total, other adverse events",5,MedDRA 10.0,13,NA,
NCT00281580,E7,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),TRUE,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),"Total, serious adverse events",0,MedDRA 10.0,0,47,
NCT00281580,E7,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),TRUE,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),"Total, other adverse events",5,MedDRA 10.0,3,NA,
NCT00281580,E8,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),TRUE,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),"Total, serious adverse events",0,MedDRA 10.0,0,143,
NCT00281580,E8,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),TRUE,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),"Total, other adverse events",5,MedDRA 10.0,9,NA,
NCT00281580,E9,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),TRUE,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),"Total, serious adverse events",0,MedDRA 10.0,0,129,
NCT00281580,E9,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),TRUE,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),"Total, other adverse events",5,MedDRA 10.0,13,NA,
NCT00368277,E1,Aliskiren,FALSE,,"Total, serious adverse events",0,MedDRA,35,452,Aliskiren based regimen
NCT00368277,E1,Aliskiren,FALSE,,"Total, other adverse events",5,MedDRA,170,452,Aliskiren based regimen
NCT00368277,E2,Ramipril,FALSE,,"Total, serious adverse events",0,MedDRA,27,444,Ramipril based regimen
NCT00368277,E2,Ramipril,FALSE,,"Total, other adverse events",5,MedDRA,181,444,Ramipril based regimen
NCT00413049,E1,Valsartan/Amlodipine 80/5 mg,TRUE,Valsartan/Amlodipine 80/5 mg,"Total, serious adverse events",0,MedDRA,4,349,"1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures."
NCT00413049,E1,Valsartan/Amlodipine 80/5 mg,TRUE,Valsartan/Amlodipine 80/5 mg,"Total, other adverse events",5,,0,349,"1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures."
NCT00413049,E2,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, serious adverse events",0,MedDRA,2,349,"1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures."
NCT00413049,E2,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, other adverse events",5,,0,349,"1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures."
NCT00413413,E1,Valsartan/Amlodipine 80/5 mg,TRUE,Valsartan/Amlodipine 80/5 mg,"Total, serious adverse events",0,MedDRA,4,308,"1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"
NCT00413413,E1,Valsartan/Amlodipine 80/5 mg,TRUE,Valsartan/Amlodipine 80/5 mg,"Total, other adverse events",5,,0,308,"1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"
NCT00413413,E2,Valsartan 80 mg,TRUE,Valsartan 80 mg,"Total, serious adverse events",0,MedDRA,0,307,"1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"
NCT00413413,E2,Valsartan 80 mg,TRUE,Valsartan 80 mg,"Total, other adverse events",5,,0,307,"1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"
NCT00413413,E3,Valsartan 160 mg,TRUE,Valsartan 160 mg,"Total, serious adverse events",0,MedDRA,4,303,"1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"
NCT00413413,E3,Valsartan 160 mg,TRUE,Valsartan 160 mg,"Total, other adverse events",5,,0,303,"1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"
NCT00425373,E1,Placebo,TRUE,Placebo,"Total, serious adverse events",0,MedDRA,2,166,4 tablet and 2 capsule placebos taken once daily
NCT00425373,E1,Placebo,TRUE,Placebo,"Total, other adverse events",5,MedDRA,17,166,4 tablet and 2 capsule placebos taken once daily
NCT00425373,E2,Valsartan 40 mg,TRUE,Valsartan 40 mg,"Total, serious adverse events",0,MedDRA,0,169,Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E2,Valsartan 40 mg,TRUE,Valsartan 40 mg,"Total, other adverse events",5,MedDRA,23,169,Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E3,Valsartan 80 mg,TRUE,Valsartan 80 mg,"Total, serious adverse events",0,MedDRA,0,163,Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E3,Valsartan 80 mg,TRUE,Valsartan 80 mg,"Total, other adverse events",5,MedDRA,19,163,Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E4,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,"Total, serious adverse events",0,MedDRA,1,161,Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
NCT00425373,E4,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,"Total, other adverse events",5,MedDRA,12,161,Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
NCT00425373,E5,Valsartan + Amlodipine 40/2.5 mg,TRUE,Valsartan + Amlodipine 40/2.5 mg,"Total, serious adverse events",0,MedDRA,0,159,Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E5,Valsartan + Amlodipine 40/2.5 mg,TRUE,Valsartan + Amlodipine 40/2.5 mg,"Total, other adverse events",5,MedDRA,17,159,Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E6,Valsartan + Amlodipine 80/2.5 mg,TRUE,Valsartan + Amlodipine 80/2.5 mg,"Total, serious adverse events",0,MedDRA,1,160,Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E6,Valsartan + Amlodipine 80/2.5 mg,TRUE,Valsartan + Amlodipine 80/2.5 mg,"Total, other adverse events",5,MedDRA,9,160,Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E7,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, serious adverse events",0,MedDRA,0,161,Amlodipine 2.5 mg 2 capsules plus 4 tablet placebos taken once daily
NCT00425373,E7,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, other adverse events",5,MedDRA,12,161,Amlodipine 2.5 mg 2 capsules plus 4 tablet placebos taken once daily
NCT00425373,E8,Valsartan + Amlodipine 40/5 mg,TRUE,Valsartan + Amlodipine 40/5 mg,"Total, serious adverse events",0,MedDRA,1,167,Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E8,Valsartan + Amlodipine 40/5 mg,TRUE,Valsartan + Amlodipine 40/5 mg,"Total, other adverse events",5,MedDRA,20,167,Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E9,Valsartan + Amlodipine 80/5 mg,TRUE,Valsartan + Amlodipine 80/5 mg,"Total, serious adverse events",0,MedDRA,0,162,Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00425373,E9,Valsartan + Amlodipine 80/5 mg,TRUE,Valsartan + Amlodipine 80/5 mg,"Total, other adverse events",5,MedDRA,14,162,Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
NCT00529451,E1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, serious adverse events",0,MedDRA,1,331,Aliskiren 300 mg once daily
NCT00529451,E1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, other adverse events",5,MedDRA,4,331,Aliskiren 300 mg once daily
NCT00529451,E2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,"Total, serious adverse events",0,MedDRA,2,323,Aliskiren 150 mg once daily
NCT00529451,E2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,"Total, other adverse events",5,MedDRA,3,323,Aliskiren 150 mg once daily
NCT00529451,E3,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,"Total, serious adverse events",0,MedDRA,3,332,Aliskiren 75 mg once daily
NCT00529451,E3,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,"Total, other adverse events",5,MedDRA,2,332,Aliskiren 75 mg once daily
NCT00529451,E4,Ramipril 5 mg,TRUE,Ramipril 5 mg,"Total, serious adverse events",0,MedDRA,1,329,Ramipril 5 mg once daily
NCT00529451,E4,Ramipril 5 mg,TRUE,Ramipril 5 mg,"Total, other adverse events",5,MedDRA,17,329,Ramipril 5 mg once daily
NCT00546754,E1,Losartan 50 mg/HCTZ 12.5 mg,TRUE,Losartan 50 mg/HCTZ 12.5 mg,"Total, serious adverse events",0,MedDRA 12.0,11,425,Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure.
NCT00546754,E1,Losartan 50 mg/HCTZ 12.5 mg,TRUE,Losartan 50 mg/HCTZ 12.5 mg,"Total, other adverse events",0,MedDRA 12.0,56,425,Patients could be titrated up from losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg to losartan 100 mg/HCTZ 25 mg only if needed to achieve target blood pressure.
NCT00546754,E2,Valsartan 80 mg/HCTZ 12.5 mg,TRUE,Valsartan 80 mg/HCTZ 12.5 mg,"Total, serious adverse events",0,MedDRA 12.0,5,383,Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure.
NCT00546754,E2,Valsartan 80 mg/HCTZ 12.5 mg,TRUE,Valsartan 80 mg/HCTZ 12.5 mg,"Total, other adverse events",0,MedDRA 12.0,57,383,Patients could be titrated up from valsartan 80 mg/HCTZ 12.5 mg to valsartan 160 mg/HCTZ 25 mg only if needed to achieve target blood pressure.
NCT00550953,E1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,TRUE,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,"Total, serious adverse events",0,MedDRA 11.0,1,156,"T40/A5 tablet, oral, once daily in the morning"
NCT00550953,E1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,TRUE,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,"Total, other adverse events",5,MedDRA 11.0,19,156,"T40/A5 tablet, oral, once daily in the morning"
NCT00550953,E2,Telmisartan 40 mg Monotherapy,TRUE,Telmisartan 40 mg Monotherapy,"Total, serious adverse events",0,MedDRA 11.0,0,158,"A5 capsule, oral, once daily in the morning"
NCT00550953,E2,Telmisartan 40 mg Monotherapy,TRUE,Telmisartan 40 mg Monotherapy,"Total, other adverse events",5,MedDRA 11.0,16,158,"A5 capsule, oral, once daily in the morning"
NCT00553267,E1,Amlodipine 10mg,TRUE,Amlodipine 10mg,"Total, serious adverse events",0,MedDRA 11.1,1,NA,
NCT00553267,E1,Amlodipine 10mg,TRUE,Amlodipine 10mg,"Total, other adverse events",5,MedDRA 11.1,22,NA,
NCT00553267,E2,Telmisartan 40mg and Amlodipine 10mg,TRUE,Telmisartan 40mg and Amlodipine 10mg,"Total, serious adverse events",0,MedDRA 11.1,3,NA,
NCT00553267,E2,Telmisartan 40mg and Amlodipine 10mg,TRUE,Telmisartan 40mg and Amlodipine 10mg,"Total, other adverse events",5,MedDRA 11.1,21,NA,
NCT00553267,E3,Telmisartan 80mg and Amlodipine 10mg,TRUE,Telmisartan 80mg and Amlodipine 10mg,"Total, serious adverse events",0,MedDRA 11.1,0,NA,
NCT00553267,E3,Telmisartan 80mg and Amlodipine 10mg,TRUE,Telmisartan 80mg and Amlodipine 10mg,"Total, other adverse events",5,MedDRA 11.1,27,NA,
NCT00558064,E1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,TRUE,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,"Total, serious adverse events",0,MedDRA 11.1,1,269,"T40/A5 tablet, oral, once daily in the morning"
NCT00558064,E1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,TRUE,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,"Total, other adverse events",5,MedDRA 11.1,25,269,"T40/A5 tablet, oral, once daily in the morning"
NCT00558064,E2,Amlodipine 5 mg Monotherapy,TRUE,Amlodipine 5 mg Monotherapy,"Total, serious adverse events",0,MedDRA 11.1,2,262,"A5 capsule, oral, once daily in the morning"
NCT00558064,E2,Amlodipine 5 mg Monotherapy,TRUE,Amlodipine 5 mg Monotherapy,"Total, other adverse events",5,MedDRA 11.1,34,262,"A5 capsule, oral, once daily in the morning"
NCT00558428,E1,Amlodipine 5mg,TRUE,Amlodipine 5mg,"Total, serious adverse events",0,MedDRA 11.0,2,267,
NCT00558428,E1,Amlodipine 5mg,TRUE,Amlodipine 5mg,"Total, other adverse events",5,MedDRA 11.0,22,267,
NCT00558428,E2,Amlodipine 10mg,TRUE,Amlodipine 10mg,"Total, serious adverse events",0,MedDRA 11.0,1,276,
NCT00558428,E2,Amlodipine 10mg,TRUE,Amlodipine 10mg,"Total, other adverse events",5,MedDRA 11.0,74,276,
NCT00558428,E3,Telmisartan 40mg and Amlodipine 5mg,TRUE,Telmisartan 40mg and Amlodipine 5mg,"Total, serious adverse events",0,MedDRA 11.0,2,277,
NCT00558428,E3,Telmisartan 40mg and Amlodipine 5mg,TRUE,Telmisartan 40mg and Amlodipine 5mg,"Total, other adverse events",5,MedDRA 11.0,14,277,
NCT00558428,E4,Telmisartan 80mg and Amlodipine 5mg,TRUE,Telmisartan 80mg and Amlodipine 5mg,"Total, serious adverse events",0,MedDRA 11.0,1,277,
NCT00558428,E4,Telmisartan 80mg and Amlodipine 5mg,TRUE,Telmisartan 80mg and Amlodipine 5mg,"Total, other adverse events",5,MedDRA 11.0,10,277,
NCT00591578,E1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,"Total, serious adverse events",0,MedDRA 11.1,8,327,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
Open Label Extension: At Week 24/completion of the double-blind treatment phase, participants could elect to continue in 28 week, open-label extension (OLE) phase. All participants who elected to participate in the OLE phase initiated treatment with azilsartan medoxomil 40 mg, tablets, orally, independent of their double-blind treatment assignment. Investigators may have added, in a step-wise fashion, hydrochlorothiazide 12.5 mg, followed by hydrochlorothiazide 25 mg, followed by other antihypertensive medications (except angiotensin II receptor blockers) as needed to achieve target blood pressure (<140/90 mm Hg or <130/80 mm Hg for diabetics)."
NCT00591578,E1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,"Total, other adverse events",5,MedDRA 11.1,77,327,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
Open Label Extension: At Week 24/completion of the double-blind treatment phase, participants could elect to continue in 28 week, open-label extension (OLE) phase. All participants who elected to participate in the OLE phase initiated treatment with azilsartan medoxomil 40 mg, tablets, orally, independent of their double-blind treatment assignment. Investigators may have added, in a step-wise fashion, hydrochlorothiazide 12.5 mg, followed by hydrochlorothiazide 25 mg, followed by other antihypertensive medications (except angiotensin II receptor blockers) as needed to achieve target blood pressure (<140/90 mm Hg or <130/80 mm Hg for diabetics)."
NCT00591578,E2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,"Total, serious adverse events",0,MedDRA 11.1,5,329,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
Open Label Extension: At Week 24/completion of the double-blind treatment phase, participants could elect to continue in 28 week, open-label extension (OLE) phase. All participants who elected to participate in the OLE phase initiated treatment with azilsartan medoxomil 40 mg, tablets, orally, independent of their double-blind treatment assignment. Investigators may have added, in a step-wise fashion, hydrochlorothiazide 12.5 mg, followed by hydrochlorothiazide 25 mg, followed by other antihypertensive medications (except angiotensin II receptor blockers) as needed to achieve target blood pressure (<140/90 mm Hg or <130/80 mm Hg for diabetics)."
NCT00591578,E2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,"Total, other adverse events",5,MedDRA 11.1,74,329,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
Open Label Extension: At Week 24/completion of the double-blind treatment phase, participants could elect to continue in 28 week, open-label extension (OLE) phase. All participants who elected to participate in the OLE phase initiated treatment with azilsartan medoxomil 40 mg, tablets, orally, independent of their double-blind treatment assignment. Investigators may have added, in a step-wise fashion, hydrochlorothiazide 12.5 mg, followed by hydrochlorothiazide 25 mg, followed by other antihypertensive medications (except angiotensin II receptor blockers) as needed to achieve target blood pressure (<140/90 mm Hg or <130/80 mm Hg for diabetics)."
NCT00591578,E3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,"Total, serious adverse events",0,MedDRA 11.1,8,326,"Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks."
NCT00591578,E3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,"Total, other adverse events",5,MedDRA 11.1,53,326,"Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks."
NCT00591578,E4,Open Label Extension,FALSE,,"Total, serious adverse events",0,MedDRA 11.1,4,170,"Azilsartan medoxomil 40 mg, tablets, orally, independent of participantâ€™s double-blind treatment assignment. Investigators may have added, in a step-wise fashion, hydrochlorothiazide 12.5 mg, followed by hydrochlorothiazide 25 mg, followed by other antihypertensive medications (except angiotensin II receptor blockers) as needed to achieve target blood pressure (<140/90 mm Hg or <130/80 mm Hg for diabetics)."
NCT00591578,E4,Open Label Extension,FALSE,,"Total, other adverse events",5,MedDRA 11.1,16,170,"Azilsartan medoxomil 40 mg, tablets, orally, independent of participantâ€™s double-blind treatment assignment. Investigators may have added, in a step-wise fashion, hydrochlorothiazide 12.5 mg, followed by hydrochlorothiazide 25 mg, followed by other antihypertensive medications (except angiotensin II receptor blockers) as needed to achieve target blood pressure (<140/90 mm Hg or <130/80 mm Hg for diabetics)."
NCT00614380,E1,Telmisartan 40mg and Amlodipine 5mg,TRUE,Telmisartan 40mg and Amlodipine 5mg,"Total, serious adverse events",0,MedDRA 11.1,22,976,
NCT00614380,E1,Telmisartan 40mg and Amlodipine 5mg,TRUE,Telmisartan 40mg and Amlodipine 5mg,"Total, other adverse events",5,MedDRA version 11.1,57,976,
NCT00614380,E2,Telmisartan 80mg and Amlodipine 5mg,TRUE,Telmisartan 80mg and Amlodipine 5mg,"Total, serious adverse events",0,MedDRA 11.1,6,397,
NCT00614380,E2,Telmisartan 80mg and Amlodipine 5mg,TRUE,Telmisartan 80mg and Amlodipine 5mg,"Total, other adverse events",5,MedDRA version 11.1,45,397,
NCT00624052,E1,Telmisartan 40mg and Amlodipine 10mg,TRUE,Telmisartan 40mg and Amlodipine 10mg,"Total, serious adverse events",0,12.0,4,838,The 838 participants in the telmisartan 40mg/amlodipine 10mg group includes all participants
NCT00624052,E1,Telmisartan 40mg and Amlodipine 10mg,TRUE,Telmisartan 40mg and Amlodipine 10mg,"Total, other adverse events",5,,0,838,The 838 participants in the telmisartan 40mg/amlodipine 10mg group includes all participants
NCT00624052,E2,Telmisartan 80mg and Amlodipine 10mg,FALSE,,"Total, serious adverse events",0,12.0,13,611,The 611 participants in the telmisartan 80mg/amlodipine 10mg (T80/A10) group include 436 patients in the randomised T80/A10 group + 91 patients in the uptitrated T80/A10 group + XX patients in the T80/A10 + add-on group
NCT00624052,E2,Telmisartan 80mg and Amlodipine 10mg,FALSE,,"Total, other adverse events",5,,0,611,The 611 participants in the telmisartan 80mg/amlodipine 10mg (T80/A10) group include 436 patients in the randomised T80/A10 group + 91 patients in the uptitrated T80/A10 group + XX patients in the T80/A10 + add-on group
NCT00631917,E1,Aliskiren,TRUE,Aliskiren,"Total, serious adverse events",0,MedDRA,28,375,"For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."
NCT00631917,E1,Aliskiren,TRUE,Aliskiren,"Total, other adverse events",5,MedDRA,163,375,"For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."
NCT00631917,E2,Ramipril,TRUE,Ramipril,"Total, serious adverse events",0,MedDRA,22,399,For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
NCT00631917,E2,Ramipril,TRUE,Ramipril,"Total, other adverse events",5,MedDRA,176,399,For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
NCT00649389,E1,OM40/AML10,TRUE,OM40/AML10,"Total, serious adverse events",0,MedDRA (11.0),9,596,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily."
NCT00649389,E1,OM40/AML10,TRUE,OM40/AML10,"Total, other adverse events",3,MedDRA (11.0),210,596,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily."
NCT00649389,E2,OM40/HCTZ25,TRUE,OM40/HCTZ25,"Total, serious adverse events",0,MedDRA (11.0),7,580,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily."
NCT00649389,E2,OM40/HCTZ25,TRUE,OM40/HCTZ25,"Total, other adverse events",3,MedDRA (11.0),210,580,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily."
NCT00649389,E3,AML10/HCTZ25,TRUE,AML10/HCTZ25,"Total, serious adverse events",0,MedDRA (11.0),9,552,"Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily."
NCT00649389,E3,AML10/HCTZ25,TRUE,AML10/HCTZ25,"Total, other adverse events",3,MedDRA (11.0),212,552,"Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily."
NCT00649389,E4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,"Total, serious adverse events",0,MedDRA (11.0),10,574,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily."
NCT00649389,E4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,"Total, other adverse events",3,MedDRA (11.0),237,574,"Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily."
NCT00687973,E1,Amlodipine 5 mg,FALSE,,"Total, other adverse events",5,MedDRA,10,393,Run-in: Amlodipine 5 mg
NCT00687973,E1,Amlodipine 5 mg,FALSE,,"Total, serious adverse events",0,MedDRA,3,393,Run-in: Amlodipine 5 mg
NCT00687973,E2,Valsartan/Amlodipine 160/10 mg,TRUE,Valsartan/Amlodipine 160/10 mg,"Total, serious adverse events",0,MedDRA,4,193,"Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."
NCT00687973,E2,Valsartan/Amlodipine 160/10 mg,TRUE,Valsartan/Amlodipine 160/10 mg,"Total, other adverse events",5,MedDRA,30,193,"Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."
NCT00687973,E3,Atenolol/Amlodipine 100/10 mg,TRUE,Atenolol/Amlodipine 100/10 mg,"Total, serious adverse events",0,MedDRA,4,200,"Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."
NCT00687973,E3,Atenolol/Amlodipine 100/10 mg,TRUE,Atenolol/Amlodipine 100/10 mg,"Total, other adverse events",5,MedDRA,31,200,"Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled."
NCT00696241,E1,Azilsartan Medoxomil 20 mg QD,TRUE,Azilsartan Medoxomil 20 mg QD,"Total, serious adverse events",0,MedDRA (11.1),8,283,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E1,Azilsartan Medoxomil 20 mg QD,TRUE,Azilsartan Medoxomil 20 mg QD,"Total, other adverse events",5,MedDRA (11.1),23,283,"Azilsartan medoxomil 20 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E2,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,"Total, serious adverse events",0,MedDRA (11.1),0,281,"Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E2,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,"Total, other adverse events",5,MedDRA (11.1),19,281,"Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E3,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,"Total, serious adverse events",0,MedDRA (11.1),1,284,"Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E3,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,"Total, other adverse events",5,MedDRA (11.1),32,284,"Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,"Total, serious adverse events",0,MedDRA (11.1),2,282,"Olmesartan 40 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,"Total, other adverse events",5,MedDRA (11.1),18,282,"Olmesartan 40 mg, tablets, orally, once daily for up to 6 weeks."
NCT00696241,E5,Placebo QD,TRUE,Placebo QD,"Total, serious adverse events",0,MedDRA (11.1),3,142,"Placebo-matching tablets, orally, once daily for up to 6 weeks."
NCT00696241,E5,Placebo QD,TRUE,Placebo QD,"Total, other adverse events",5,MedDRA (11.1),13,142,"Placebo-matching tablets, orally, once daily for up to 6 weeks."
NCT00696436,E1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,"Total, serious adverse events",0,MedDRA 11.1,2,280,"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
NCT00696436,E1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,"Total, other adverse events",5,MedDRA 11.1,18,280,"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
NCT00696436,E2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,"Total, serious adverse events",0,MedDRA 11.1,3,284,"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
NCT00696436,E2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,"Total, other adverse events",5,MedDRA 11.1,12,284,"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
NCT00696436,E3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,"Total, serious adverse events",0,MedDRA 11.1,3,277,"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
NCT00696436,E3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,"Total, other adverse events",5,MedDRA 11.1,21,277,"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
NCT00696436,E4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,"Total, serious adverse events",0,MedDRA 11.1,4,290,"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
NCT00696436,E4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,"Total, other adverse events",5,MedDRA 11.1,23,290,"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
NCT00696436,E5,Placebo QD,TRUE,Placebo QD,"Total, serious adverse events",0,MedDRA 11.1,2,155,"Matching placebo, orally, once daily for up to six weeks."
NCT00696436,E5,Placebo QD,TRUE,Placebo QD,"Total, other adverse events",5,MedDRA 11.1,14,155,"Matching placebo, orally, once daily for up to six weeks."
NCT00698646,E1,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,"Total, serious adverse events",0,MedDRA,3,128,At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
NCT00698646,E1,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,"Total, other adverse events",5,MedDRA,16,128,At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
NCT00698646,E2,HCTZ,TRUE,HCTZ,"Total, serious adverse events",0,MedDRA,4,128,"At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."
NCT00698646,E2,HCTZ,TRUE,HCTZ,"Total, other adverse events",5,MedDRA,27,128,"At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12."
NCT00698646,E3,Valsartan,TRUE,Valsartan,"Total, serious adverse events",0,MedDRA,3,128,"At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"
NCT00698646,E3,Valsartan,TRUE,Valsartan,"Total, other adverse events",5,MedDRA,23,128,"At week 0 patients received Valsartan 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12"
NCT00699192,E1,Amlodipine/Valsartan 5/80 mg,TRUE,Amlodipine/Valsartan 5/80 mg,"Total, serious adverse events",0,MedDRA,5,274,"1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily"
NCT00699192,E1,Amlodipine/Valsartan 5/80 mg,TRUE,Amlodipine/Valsartan 5/80 mg,"Total, other adverse events",5,,0,274,"1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily"
NCT00699192,E2,Amlodipine/Valsartan 5/40 mg,TRUE,Amlodipine/Valsartan 5/40 mg,"Total, serious adverse events",0,MedDRA,2,272,"1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily"
NCT00699192,E2,Amlodipine/Valsartan 5/40 mg,TRUE,Amlodipine/Valsartan 5/40 mg,"Total, other adverse events",5,,0,272,"1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily"
NCT00699192,E3,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, serious adverse events",0,MedDRA,1,272,"1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily"
NCT00699192,E3,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, other adverse events",5,,0,272,"1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily"
NCT00705575,E1,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),TRUE,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),"Total, serious adverse events",0,MedDRA,2,349,"During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week. Subsequently, patients were up-titrated and received aliskiren/HCTZ 300/25 mg."
NCT00705575,E1,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),TRUE,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),"Total, other adverse events",5,MedDRA,27,349,"During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week. Subsequently, patients were up-titrated and received aliskiren/HCTZ 300/25 mg."
NCT00705575,E2,Aliskiren (300 mg),TRUE,Aliskiren (300 mg),"Total, serious adverse events",0,MedDRA,4,339,"During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg."
NCT00705575,E2,Aliskiren (300 mg),TRUE,Aliskiren (300 mg),"Total, other adverse events",5,MedDRA,34,339,"During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg."
NCT00706134,E1,Placebo,TRUE,Placebo,"Total, serious adverse events",0,MedDRA,1,186,Placebo tablet taken once daily in the morning with a light meal.
NCT00706134,E1,Placebo,TRUE,Placebo,"Total, other adverse events",5,,0,186,Placebo tablet taken once daily in the morning with a light meal.
NCT00706134,E2,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,"Total, serious adverse events",0,MedDRA,2,191,Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
NCT00706134,E2,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,"Total, other adverse events",5,,0,191,Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
NCT00706134,E3,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,"Total, serious adverse events",0,MedDRA,3,189,Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
NCT00706134,E3,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,"Total, other adverse events",5,,0,189,Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
NCT00706134,E4,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, serious adverse events",0,MedDRA,0,188,Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
NCT00706134,E4,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, other adverse events",5,,0,188,Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
NCT00739973,E1,Placebo,TRUE,Placebo,"Total, serious adverse events",0,MedDRA,2,198,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."
NCT00739973,E1,Placebo,TRUE,Placebo,"Total, other adverse events",5,MedDRA,22,198,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; for this arm all the 5 pills taken were placebos."
NCT00739973,E2,Aliskiren 150 mg Tablet,FALSE,,"Total, serious adverse events",0,MedDRA,0,194,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E2,Aliskiren 150 mg Tablet,FALSE,,"Total, other adverse events",5,MedDRA,15,194,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E3,Aliskiren 300 mg Tablet,FALSE,,"Total, serious adverse events",0,MedDRA,0,203,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E3,Aliskiren 300 mg Tablet,FALSE,,"Total, other adverse events",5,MedDRA,18,203,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E4,Amlodipine 5 mg Capsule,FALSE,,"Total, serious adverse events",0,MedDRA,1,185,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E4,Amlodipine 5 mg Capsule,FALSE,,"Total, other adverse events",5,MedDRA,18,185,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E5,Amlodipine 10 mg Capsule,FALSE,,"Total, serious adverse events",0,MedDRA,1,181,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."
NCT00739973,E5,Amlodipine 10 mg Capsule,FALSE,,"Total, other adverse events",5,MedDRA,32,181,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg."
NCT00739973,E6,Aliskiren/Amlodipine 150/5 mg Tablet,FALSE,,"Total, serious adverse events",0,MedDRA,1,181,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E6,Aliskiren/Amlodipine 150/5 mg Tablet,FALSE,,"Total, other adverse events",5,MedDRA,15,181,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E7,Aliskiren/Amlodipine 150/10 mg Tablet,FALSE,,"Total, serious adverse events",0,MedDRA,2,181,"150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E7,Aliskiren/Amlodipine 150/10 mg Tablet,FALSE,,"Total, other adverse events",5,MedDRA,19,181,"150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E8,Aliskiren/Amlodipine 300/5 mg Tablet,FALSE,,"Total, serious adverse events",0,MedDRA,1,178,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E8,Aliskiren/Amlodipine 300/5 mg Tablet,FALSE,,"Total, other adverse events",5,MedDRA,8,178,"Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E9,Aliskiren/Amlodipine 300/10 mg Tablet,TRUE,Aliskiren/Amlodipine 300/10 mg Tablet,"Total, serious adverse events",0,MedDRA,1,184,"300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00739973,E9,Aliskiren/Amlodipine 300/10 mg Tablet,TRUE,Aliskiren/Amlodipine 300/10 mg Tablet,"Total, other adverse events",5,MedDRA,30,184,"300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos."
NCT00760266,E1,Aliskiren / HCTZ,FALSE,,"Total, serious adverse events",0,MedDRA,4,227,"Aliskiren HCTZ 150/12.5 mg: 1 week, Aliskiren HCTZ 300/25 mg (with or without amlodipine): 7 weeks"
NCT00760266,E1,Aliskiren / HCTZ,FALSE,,"Total, other adverse events",5,MedDRA,17,227,"Aliskiren HCTZ 150/12.5 mg: 1 week, Aliskiren HCTZ 300/25 mg (with or without amlodipine): 7 weeks"
NCT00760266,E2,HCTZ,TRUE,HCTZ,"Total, serious adverse events",0,MedDRA,3,223,"HCTZ 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks"
NCT00760266,E2,HCTZ,TRUE,HCTZ,"Total, other adverse events",5,MedDRA,26,223,"HCTZ 12.5 mg: 1 week, HCTZ 25 mg (with or without amlodipine): 7 weeks"
NCT00765674,E1,Aliskiren / Amlodipine,TRUE,Aliskiren / Amlodipine,"Total, serious adverse events",0,MedDRA,3,287,"Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."
NCT00765674,E1,Aliskiren / Amlodipine,TRUE,Aliskiren / Amlodipine,"Total, other adverse events",5,MedDRA,32,287,"Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."
NCT00765674,E2,Aliskiren / Hydrochlorothiazide,TRUE,Aliskiren / Hydrochlorothiazide,"Total, serious adverse events",0,MedDRA,2,297,"Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."
NCT00765674,E2,Aliskiren / Hydrochlorothiazide,TRUE,Aliskiren / Hydrochlorothiazide,"Total, other adverse events",5,MedDRA,17,297,"Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed."
NCT00765674,E3,Amlodipine / Hydrochlorothiazide,TRUE,Amlodipine / Hydrochlorothiazide,"Total, serious adverse events",0,MedDRA,2,295,"Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"
NCT00765674,E3,Amlodipine / Hydrochlorothiazide,TRUE,Amlodipine / Hydrochlorothiazide,"Total, other adverse events",5,MedDRA,26,295,"Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"
NCT00765674,E4,Aliskiren / Amlodipine / Hydrochlorothiazide,TRUE,Aliskiren / Amlodipine / Hydrochlorothiazide,"Total, serious adverse events",0,MedDRA,6,309,"Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"
NCT00765674,E4,Aliskiren / Amlodipine / Hydrochlorothiazide,TRUE,Aliskiren / Amlodipine / Hydrochlorothiazide,"Total, other adverse events",5,MedDRA,29,309,"Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed"
NCT00777946,E1,Aliskiren 300 mg/Amlodipine 10 mg,TRUE,Aliskiren 300 mg/Amlodipine 10 mg,"Total, serious adverse events",0,MedDRA,3,282,Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
NCT00777946,E1,Aliskiren 300 mg/Amlodipine 10 mg,TRUE,Aliskiren 300 mg/Amlodipine 10 mg,"Total, other adverse events",5,MedDRA,26,282,Participants received 1 Aliskiren/Amlodipine 300/10mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
NCT00777946,E2,Aliskiren 300 mg/Amlodipine 5 mg,TRUE,Aliskiren 300 mg/Amlodipine 5 mg,"Total, serious adverse events",0,MedDRA,4,276,Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
NCT00777946,E2,Aliskiren 300 mg/Amlodipine 5 mg,TRUE,Aliskiren 300 mg/Amlodipine 5 mg,"Total, other adverse events",5,MedDRA,6,276,Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
NCT00777946,E3,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, serious adverse events",0,MedDRA,1,260,Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
NCT00777946,E3,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, other adverse events",5,MedDRA,1,260,Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
NCT00778921,E1,Aliskiren 300mg/ Amlodipine 10mg,FALSE,,"Total, serious adverse events",0,MedDRA,4,279,Aliskiren 300mg/ Amlodipine 10mg
NCT00778921,E1,Aliskiren 300mg/ Amlodipine 10mg,FALSE,,"Total, other adverse events",5,MedDRA,31,279,Aliskiren 300mg/ Amlodipine 10mg
NCT00778921,E2,Aliskiren 150mg/ Amlodipine 10mg,FALSE,,"Total, serious adverse events",0,MedDRA,1,283,Aliskiren 150mg/ Amlodipine 10mg
NCT00778921,E2,Aliskiren 150mg/ Amlodipine 10mg,FALSE,,"Total, other adverse events",5,MedDRA,35,283,Aliskiren 150mg/ Amlodipine 10mg
NCT00778921,E3,Amlodipine 10mg,FALSE,,"Total, serious adverse events",0,MedDRA,0,281,Amlodipine 10mg
NCT00778921,E3,Amlodipine 10mg,FALSE,,"Total, other adverse events",5,MedDRA,40,281,Amlodipine 10mg
NCT00787605,E1,Aliskiren/HCTZ,TRUE,Aliskiren/HCTZ,"Total, serious adverse events",0,MedDRA,3,428,Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
NCT00787605,E1,Aliskiren/HCTZ,TRUE,Aliskiren/HCTZ,"Total, other adverse events",5,MedDRA,28,428,Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
NCT00787605,E2,Amlodipine,TRUE,Amlodipine,"Total, serious adverse events",0,MedDRA,4,431,Amlodipine 5 mg for 1 week followed by 10 mg for 7 weeks
NCT00787605,E2,Amlodipine,TRUE,Amlodipine,"Total, other adverse events",5,MedDRA,86,431,Amlodipine 5 mg for 1 week followed by 10 mg for 7 weeks
NCT00797316,E1,Aliskiren/HCTZ,TRUE,Aliskiren/HCTZ,"Total, serious adverse events",0,MedDRA,3,267,Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
NCT00797316,E1,Aliskiren/HCTZ,TRUE,Aliskiren/HCTZ,"Total, other adverse events",5,MedDRA,13,267,Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
NCT00797316,E2,Aliskiren,TRUE,Aliskiren,"Total, serious adverse events",0,MedDRA,4,265,Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
NCT00797316,E2,Aliskiren,TRUE,Aliskiren,"Total, other adverse events",5,MedDRA,18,265,Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
NCT00809926,E1,Valsartan/ Aliskiren,FALSE,,"Total, serious adverse events",0,MedDRA,5,232,Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
NCT00809926,E1,Valsartan/ Aliskiren,FALSE,,"Total, other adverse events",5,MedDRA,14,232,Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
NCT00809926,E2,Valsartan,TRUE,Valsartan,"Total, serious adverse events",0,MedDRA,3,219,Valsartan (160mg) for 2weeks followed by forced titration toValsartan (320mg) for the remaining 6 weeks
NCT00809926,E2,Valsartan,TRUE,Valsartan,"Total, other adverse events",5,MedDRA,15,219,Valsartan (160mg) for 2weeks followed by forced titration toValsartan (320mg) for the remaining 6 weeks
NCT00841672,E1,Aliskiren/Amlodipine 300/10 mg Tablet,TRUE,Aliskiren/Amlodipine 300/10 mg Tablet,"Total, serious adverse events",0,MedDRA,0,243,"Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."
NCT00841672,E1,Aliskiren/Amlodipine 300/10 mg Tablet,TRUE,Aliskiren/Amlodipine 300/10 mg Tablet,"Total, other adverse events",5,MedDRA,41,243,"Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg."
NCT00841672,E2,Amlodipine 10 mg Capsule,TRUE,Amlodipine 10 mg Capsule,"Total, serious adverse events",0,MedDRA,3,241,"Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."
NCT00841672,E2,Amlodipine 10 mg Capsule,TRUE,Amlodipine 10 mg Capsule,"Total, other adverse events",5,MedDRA,56,241,"Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg."
NCT00846365,E1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,TRUE,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,"Total, serious adverse events",0,MedDRA 13.0,4,372,"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
NCT00846365,E1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,TRUE,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,"Total, other adverse events",5,MedDRA 13.0,66,372,"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
NCT00846365,E2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,TRUE,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,"Total, serious adverse events",0,MedDRA 13.0,8,357,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
NCT00846365,E2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,TRUE,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,"Total, other adverse events",5,MedDRA 13.0,72,357,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
NCT00846365,E3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,"Total, serious adverse events",0,MedDRA 13.0,6,356,"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
NCT00846365,E3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,"Total, other adverse events",5,MedDRA 13.0,56,356,"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
NCT00853957,E1,Aliskiren/Amlodipine,TRUE,Aliskiren/Amlodipine,"Total, serious adverse events",0,MedDRA,1,220,Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
NCT00853957,E1,Aliskiren/Amlodipine,TRUE,Aliskiren/Amlodipine,"Total, other adverse events",5,MedDRA,25,220,Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
NCT00853957,E2,Amlodipine,TRUE,Amlodipine,"Total, serious adverse events",0,MedDRA,1,223,Amlodipine 5mg titrated to 10 mg
NCT00853957,E2,Amlodipine,TRUE,Amlodipine,"Total, other adverse events",5,MedDRA,31,223,Amlodipine 5mg titrated to 10 mg
NCT00860262,E1,T80+A10,TRUE,T80+A10,"Total, serious adverse events",0,MedDRA 12.1,3,421,Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)
NCT00860262,E1,T80+A10,TRUE,T80+A10,"Total, other adverse events",5,MedDRA 12.1,67,421,Telmisartan 80 mg plus Amlodipine 10 mg once daily (T80+A10)
NCT00860262,E2,Telmisartan 80 mg,TRUE,Telmisartan 80 mg,"Total, serious adverse events",0,MedDRA 12.1,2,217,Telmisartan 80 mg once daily (T80)
NCT00860262,E2,Telmisartan 80 mg,TRUE,Telmisartan 80 mg,"Total, other adverse events",5,MedDRA 12.1,25,217,Telmisartan 80 mg once daily (T80)
NCT00860262,E3,Amlodipine 10 mg,TRUE,Amlodipine 10 mg,"Total, serious adverse events",0,MedDRA 12.1,2,220,Amlodipine 10 mg once daily (A10)
NCT00860262,E3,Amlodipine 10 mg,TRUE,Amlodipine 10 mg,"Total, other adverse events",5,MedDRA 12.1,42,220,Amlodipine 10 mg once daily (A10)
NCT00865020,E1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, serious adverse events",0,MedDRA,3,411,Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
NCT00865020,E1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,"Total, other adverse events",5,MedDRA,15,411,Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
NCT00865020,E2,Telmisartan 80 mg,TRUE,Telmisartan 80 mg,"Total, serious adverse events",0,MedDRA,5,403,Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
NCT00865020,E2,Telmisartan 80 mg,TRUE,Telmisartan 80 mg,"Total, other adverse events",5,MedDRA,32,403,Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
NCT00877929,E1,Telmisartan 80 mg + Amlodipine 10 mg,TRUE,Telmisartan 80 mg + Amlodipine 10 mg,"Total, serious adverse events",0,MedDRA version 13.0,3,352,Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.
NCT00877929,E1,Telmisartan 80 mg + Amlodipine 10 mg,TRUE,Telmisartan 80 mg + Amlodipine 10 mg,"Total, other adverse events",5,MedDRA (13.0),62,352,Once daily Telmisartan 80 mg (T80) / Amlodipine 5 mg (A5) tablet for first 2 weeks then Telmisartan 80 mg (T80) / Amlodipine 10 mg (A10) tablet for 6 weeks.
NCT00877929,E2,Amlodipine 10 mg,TRUE,Amlodipine 10 mg,"Total, serious adverse events",0,MedDRA version 13.0,4,354,Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.
NCT00877929,E2,Amlodipine 10 mg,TRUE,Amlodipine 10 mg,"Total, other adverse events",5,MedDRA (13.0),71,354,Once daily Placebo / Amlodipine 5 mg (A5) tablet for first 2 weeks then Placebo / Amlodipine 10 mg (A10) tablet for 6 weeks.
NCT00902304,E1,Pre-randomization,FALSE,,"Total, serious adverse events",0,MedDRA,27,2185,Pre-randomization
NCT00902304,E1,Pre-randomization,FALSE,,"Total, other adverse events",5,MedDRA,95,2185,Pre-randomization
NCT00902304,E2,Usual Care,TRUE,Usual Care,"Total, serious adverse events",0,MedDRA,24,524,Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
NCT00902304,E2,Usual Care,TRUE,Usual Care,"Total, other adverse events",5,MedDRA,47,524,Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
NCT00902304,E3,Monotherapy (Initial Monotherapy Arm),TRUE,Monotherapy (Initial Monotherapy Arm),"Total, serious adverse events",0,MedDRA,15,360,"Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study."
NCT00902304,E3,Monotherapy (Initial Monotherapy Arm),TRUE,Monotherapy (Initial Monotherapy Arm),"Total, other adverse events",5,MedDRA,36,360,"Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study."
NCT00902304,E4,Combination (Initial Combination Therapy Arm),TRUE,Combination (Initial Combination Therapy Arm),"Total, serious adverse events",0,MedDRA,22,678,"Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study."
NCT00902304,E4,Combination (Initial Combination Therapy Arm),TRUE,Combination (Initial Combination Therapy Arm),"Total, other adverse events",5,MedDRA,105,678,"Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study."
NCT00902538,E1,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,TRUE,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,"Total, serious adverse events",0,MedDRA (11.0),18,2204,"The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."
NCT00902538,E1,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,TRUE,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,"Total, other adverse events",3,MedDRA (11.0),113,2204,"The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."
NCT00902538,E2,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,TRUE,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,"Total, serious adverse events",0,MedDRA (11.0),15,269,"Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."
NCT00902538,E2,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,TRUE,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,"Total, other adverse events",3,MedDRA (11.0),7,269,"Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."
NCT00902538,E3,OLM 40-AML 10-HCTZ 25,TRUE,OLM 40-AML 10-HCTZ 25,"Total, serious adverse events",0,MedDRA (11.0),3,270,"Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."
NCT00902538,E3,OLM 40-AML 10-HCTZ 25,TRUE,OLM 40-AML 10-HCTZ 25,"Total, other adverse events",3,MedDRA (11.0),7,270,"Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."
NCT00923091,E1,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg,"Total, serious adverse events",0,MedDRA (11.0),55,329,
NCT00923091,E1,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg,"Total, other adverse events",3,MedDRA (11.0),12,329,
NCT00923091,E2,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,"Total, serious adverse events",0,MedDRA (11.0),9,334,
NCT00923091,E2,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,"Total, other adverse events",3,MedDRA (11.0),44,334,
NCT00923091,E3,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,"Total, serious adverse events",0,MedDRA (11.0),22,331,
NCT00923091,E3,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,"Total, other adverse events",3,MedDRA (11.0),13,331,
NCT00923091,E4,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,"Total, serious adverse events",0,MedDRA (11.0),3,329,
NCT00923091,E4,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,"Total, other adverse events",3,MedDRA (11.0),39,329,
NCT00923091,E5,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg,"Total, serious adverse events",0,MedDRA (11.0),7,332,
NCT00923091,E5,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg,TRUE,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg,"Total, other adverse events",3,MedDRA (11.0),45,332,
NCT00923091,E6,Olmesartan/Amlodipine 20mg/5mg,TRUE,Olmesartan/Amlodipine 20mg/5mg,"Total, serious adverse events",0,MedDRA (11.0),1,333,
NCT00923091,E6,Olmesartan/Amlodipine 20mg/5mg,TRUE,Olmesartan/Amlodipine 20mg/5mg,"Total, other adverse events",3,MedDRA (11.0),26,333,
NCT00923091,E7,Olmesartan/Amlodipine 40mg/5mg,TRUE,Olmesartan/Amlodipine 40mg/5mg,"Total, serious adverse events",0,MedDRA (11.0),5,332,
NCT00923091,E7,Olmesartan/Amlodipine 40mg/5mg,TRUE,Olmesartan/Amlodipine 40mg/5mg,"Total, other adverse events",3,MedDRA (11.0),38,332,
NCT00923091,E8,Olmesartan/Amlodipine 40mg/10mg,TRUE,Olmesartan/Amlodipine 40mg/10mg,"Total, serious adverse events",0,MedDRA (11.0),7,325,
NCT00923091,E8,Olmesartan/Amlodipine 40mg/10mg,TRUE,Olmesartan/Amlodipine 40mg/10mg,"Total, other adverse events",3,MedDRA (11.0),30,325,
NCT00926289,E1,Telmisartan 40/80 mg,TRUE,Telmisartan 40/80 mg,"Total, serious adverse events",0,Meddra 13.0,1,294,Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks
NCT00926289,E1,Telmisartan 40/80 mg,TRUE,Telmisartan 40/80 mg,"Total, other adverse events",5,,0,294,Telmisartan 40mg once daily for 1 week with forced titration to 80 mg for 6 weeks
NCT00926289,E2,Telmisartan 40/80 mg + HCTZ 12.5/25 mg,TRUE,Telmisartan 40/80 mg + HCTZ 12.5/25 mg,"Total, serious adverse events",0,Meddra 13.0,0,594,fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks
NCT00926289,E2,Telmisartan 40/80 mg + HCTZ 12.5/25 mg,TRUE,Telmisartan 40/80 mg + HCTZ 12.5/25 mg,"Total, other adverse events",5,,0,594,fixed combination of Telmisartan 40mg and HCTZ 12.5 mg once daily for 1 week with forced titration to T80+HCTZ25 for 6 weeks
NCT00927394,E1,Combination Therapy: Aliskiren + Valsartan,TRUE,Combination Therapy: Aliskiren + Valsartan,"Total, serious adverse events",0,MedDRA,9,574,"To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks."
NCT00927394,E1,Combination Therapy: Aliskiren + Valsartan,TRUE,Combination Therapy: Aliskiren + Valsartan,"Total, other adverse events",5,MedDRA,34,574,"To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks."
NCT00927394,E2,Monotherapy: Valsartan,TRUE,Monotherapy: Valsartan,"Total, serious adverse events",0,MedDRA,9,565,"To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks."
NCT00927394,E2,Monotherapy: Valsartan,TRUE,Monotherapy: Valsartan,"Total, other adverse events",5,MedDRA,36,565,"To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks."
NCT00931710,E1,Valsartan / Amlodipine / HCTZ,FALSE,,"Total, serious adverse events",0,MedDRA,1,241,Valsartan / amlodipine / HCTZ
NCT00931710,E1,Valsartan / Amlodipine / HCTZ,FALSE,,"Total, other adverse events",5,MedDRA,13,241,Valsartan / amlodipine / HCTZ
NCT00931710,E2,Losartan / HCTZ,FALSE,,"Total, serious adverse events",0,MedDRA,2,247,Losartan / HCTZ
NCT00931710,E2,Losartan / HCTZ,FALSE,,"Total, other adverse events",5,MedDRA,8,247,Losartan / HCTZ
NCT00942994,E1,Aliskiren / Amlodipine / HCTZ,TRUE,Aliskiren / Amlodipine / HCTZ,"Total, serious adverse events",0,MedDRA,0,202,"At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."
NCT00942994,E1,Aliskiren / Amlodipine / HCTZ,TRUE,Aliskiren / Amlodipine / HCTZ,"Total, other adverse events",5,MedDRA,22,202,"At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg."
NCT00942994,E2,Aliskiren / Amlodipine,TRUE,Aliskiren / Amlodipine,"Total, serious adverse events",0,MedDRA,3,209,"At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."
NCT00942994,E2,Aliskiren / Amlodipine,TRUE,Aliskiren / Amlodipine,"Total, other adverse events",5,MedDRA,18,209,"At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg."
NCT00949884,E1,Olmesartan,TRUE,Olmesartan,"Total, serious adverse events",0,MedDRA 12.1,0,420,Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
NCT00949884,E1,Olmesartan,TRUE,Olmesartan,"Total, other adverse events",0,MedDRA 12.1,133,420,Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
NCT00949884,E2,Placebo Followed by Olmesartan,TRUE,Placebo Followed by Olmesartan,"Total, serious adverse events",0,MedDRA 12.1,0,52,"Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks"
NCT00949884,E2,Placebo Followed by Olmesartan,TRUE,Placebo Followed by Olmesartan,"Total, other adverse events",0,MedDRA 12.1,21,52,"Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks"
NCT00949884,E3,Losartan,TRUE,Losartan,"Total, serious adverse events",0,MedDRA 12.1,4,469,"Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks"
NCT00949884,E3,Losartan,TRUE,Losartan,"Total, other adverse events",0,MedDRA 12.1,148,469,"Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks"
NCT00996281,E1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,"Total, serious adverse events",0,MedDRA (14.0),24,418,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg. Additional antihypertensive agents could be added as needed to achieve blood pressure control."
NCT00996281,E1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,"Total, other adverse events",5,MedDRA (14.0),217,418,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg. Additional antihypertensive agents could be added as needed to achieve blood pressure control."
NCT00996281,E2,Olmesartan Medoxomil and Hydrochlorothiazide,TRUE,Olmesartan Medoxomil and Hydrochlorothiazide,"Total, serious adverse events",0,MedDRA (14.0),26,419,"Participants in the United States: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg. Participants in Europe: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg. Additional antihypertensive agents could be added as needed to achieve blood pressure control."
NCT00996281,E2,Olmesartan Medoxomil and Hydrochlorothiazide,TRUE,Olmesartan Medoxomil and Hydrochlorothiazide,"Total, other adverse events",5,MedDRA (14.0),183,419,"Participants in the United States: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg. Participants in Europe: Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg. Additional antihypertensive agents could be added as needed to achieve blood pressure control."
NCT01001572,E1,Valsartan/Amlodipine 160/5 mg,TRUE,Valsartan/Amlodipine 160/5 mg,"Total, serious adverse events",0,MedDRA,0,329,One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks.
NCT01001572,E1,Valsartan/Amlodipine 160/5 mg,TRUE,Valsartan/Amlodipine 160/5 mg,"Total, other adverse events",5,,0,329,One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks.
NCT01001572,E2,Valsartan 160 mg,TRUE,Valsartan 160 mg,"Total, serious adverse events",0,MedDRA,1,325,One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
NCT01001572,E2,Valsartan 160 mg,TRUE,Valsartan 160 mg,"Total, other adverse events",5,,0,325,One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
NCT01033071,E1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,"Total, serious adverse events",0,MedDRA 13.0,1,355,"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
NCT01033071,E1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,"Total, other adverse events",5,MedDRA 13.0,141,355,"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
NCT01033071,E2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,"Total, serious adverse events",0,MedDRA 13.0,10,352,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
NCT01033071,E2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,"Total, other adverse events",5,MedDRA 13.0,144,352,"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
NCT01033071,E3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,"Total, serious adverse events",0,MedDRA 13.0,8,364,"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
NCT01033071,E3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,"Total, other adverse events",5,MedDRA 13.0,94,364,"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
NCT01042392,E1,Ramipril (Period II and III),FALSE,,"Total, serious adverse events",0,MedDRA,3,257,"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained â‰¥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
In period III (double-blind withdrawal): At visit 4, patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01042392,E1,Ramipril (Period II and III),FALSE,,"Total, other adverse events",5,,0,257,"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained â‰¥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
In period III (double-blind withdrawal): At visit 4, patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01042392,E2,Placebo to Ramipril (Period III),FALSE,,"Total, serious adverse events",0,MedDRA,0,118,"In period III (double-blind withdrawal): At visit 4, part of the patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01042392,E2,Placebo to Ramipril (Period III),FALSE,,"Total, other adverse events",5,,0,118,"In period III (double-blind withdrawal): At visit 4, part of the patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01042392,E3,Aliskiren (Period II and III),FALSE,,"Total, serious adverse events",0,MedDRA,1,248,"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained â‰¥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01042392,E3,Aliskiren (Period II and III),FALSE,,"Total, other adverse events",5,,0,248,"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained â‰¥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01042392,E4,Placebo to Aliskiren (Period III),FALSE,,"Total, serious adverse events",0,MedDRA,0,122,"In period III (double-blind withdrawal): At visit 4, part of patients from Aliskiren arm received placebo for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01042392,E4,Placebo to Aliskiren (Period III),FALSE,,"Total, other adverse events",5,,0,122,"In period III (double-blind withdrawal): At visit 4, part of patients from Aliskiren arm received placebo for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
NCT01167153,E1,Valsartan/Amlodipine,TRUE,Valsartan/Amlodipine,"Total, serious adverse events",0,MedDRA 10.0,0,282,"Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."
NCT01167153,E1,Valsartan/Amlodipine,TRUE,Valsartan/Amlodipine,"Total, other adverse events",5,MedDRA 10.0,14,282,"Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."
NCT01167153,E2,Nifedipine,TRUE,Nifedipine,"Total, serious adverse events",0,MedDRA 10.0,1,282,"Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."
NCT01167153,E2,Nifedipine,TRUE,Nifedipine,"Total, other adverse events",5,MedDRA 10.0,32,282,"Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."
NCT01237223,E1,Placebo (Double Blind),FALSE,,"Total, serious adverse events",0,MedDRA,0,153,"In order to adequately blind the study,patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily."
NCT01237223,E1,Placebo (Double Blind),FALSE,,"Total, other adverse events",5,MedDRA,21,153,"In order to adequately blind the study,patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily."
NCT01237223,E2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,"Total, serious adverse events",0,MedDRA,0,157,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
NCT01237223,E2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,"Total, other adverse events",5,MedDRA,21,157,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
NCT01237223,E3,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,"Total, serious adverse events",0,MedDRA,2,158,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
NCT01237223,E3,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,"Total, other adverse events",5,MedDRA,17,158,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
NCT01237223,E4,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, serious adverse events",0,MedDRA,1,158,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
NCT01237223,E4,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,"Total, other adverse events",5,MedDRA,21,158,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
NCT01237223,E5,Aliskiren/Amlodipine 150/2.5 mg,TRUE,Aliskiren/Amlodipine 150/2.5 mg,"Total, serious adverse events",0,MedDRA,0,159,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
NCT01237223,E5,Aliskiren/Amlodipine 150/2.5 mg,TRUE,Aliskiren/Amlodipine 150/2.5 mg,"Total, other adverse events",5,MedDRA,17,159,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
NCT01237223,E6,Aliskiren/Amlodipine 150/5 mg,TRUE,Aliskiren/Amlodipine 150/5 mg,"Total, serious adverse events",0,MedDRA,1,159,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
NCT01237223,E6,Aliskiren/Amlodipine 150/5 mg,TRUE,Aliskiren/Amlodipine 150/5 mg,"Total, other adverse events",5,MedDRA,19,159,"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
NCT01237223,E7,Placebo (Single-Blind run-in Period),FALSE,,"Total, serious adverse events",0,MedDRA,4,1342,"In order to adequately blind the study,patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in period (4 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily."
NCT01237223,E7,Placebo (Single-Blind run-in Period),FALSE,,"Total, other adverse events",5,MedDRA,136,1342,"In order to adequately blind the study,patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in period (4 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily."
NCT01368536,E1,Valturna,TRUE,Valturna,"Total, serious adverse events",0,,0,138,"At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."
NCT01368536,E1,Valturna,TRUE,Valturna,"Total, other adverse events",5,MedDRA,23,138,"At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks."
NCT01368536,E2,Valturna + Amlodipine,TRUE,Valturna + Amlodipine,"Total, serious adverse events",0,,0,137,"At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."
NCT01368536,E2,Valturna + Amlodipine,TRUE,Valturna + Amlodipine,"Total, other adverse events",5,MedDRA,16,137,"At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks."
NCT01368536,E3,Valturna + Chlorthalidone,TRUE,Valturna + Chlorthalidone,"Total, serious adverse events",0,,0,142,"At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."
NCT01368536,E3,Valturna + Chlorthalidone,TRUE,Valturna + Chlorthalidone,"Total, other adverse events",5,MedDRA,23,142,"At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks."
NCT01599104,E1,LCZ696 200 mg,TRUE,LCZ696 200 mg,"Total, other adverse events",2,MedDRA,48,387,LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks
NCT01599104,E1,LCZ696 200 mg,TRUE,LCZ696 200 mg,"Total, serious adverse events",0,MedDRA,1,387,LCZ696 200 mg tablet and a placebo tablet once daily for eight weeks
NCT01599104,E2,LCZ696 400 mg,TRUE,LCZ696 400 mg,"Total, other adverse events",2,MedDRA,47,385,"LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks"
NCT01599104,E2,LCZ696 400 mg,TRUE,LCZ696 400 mg,"Total, serious adverse events",0,MedDRA,1,385,"LCZ696 200 mg tablet and a placebo tablet once daily for one week, then up-titrated to 400 mg once daily for the remaining 7 weeks"
NCT01599104,E3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,"Total, other adverse events",2,MedDRA,46,389,Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks
NCT01599104,E3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,"Total, serious adverse events",0,MedDRA,7,389,Olmesartan 20 mg tablet and a placebo tablet once daily for 8 weeks
NCT01615198,E1,LCZ696,TRUE,LCZ696,"Total, serious adverse events",0,16.0,7,296,"Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd."
NCT01615198,E1,LCZ696,TRUE,LCZ696,"Total, other adverse events",2,16.0,49,296,"Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd."
NCT01615198,E2,Olmesartan,TRUE,Olmesartan,"Total, serious adverse events",0,16.0,2,292,"Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd."
NCT01615198,E2,Olmesartan,TRUE,Olmesartan,"Total, other adverse events",2,16.0,44,292,"Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd."
NCT01785472,E1,LCZ696 200 mg,TRUE,LCZ696 200 mg,"Total, serious adverse events",0,17.0,5,478,Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily
NCT01785472,E1,LCZ696 200 mg,TRUE,LCZ696 200 mg,"Total, other adverse events",2,17.0,66,478,Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily
NCT01785472,E2,LCZ696 400 mg,TRUE,LCZ696 400 mg,"Total, serious adverse events",0,17.0,3,472,"Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken."
NCT01785472,E2,LCZ696 400 mg,TRUE,LCZ696 400 mg,"Total, other adverse events",2,17.0,63,472,"Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken."
NCT01785472,E3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,"Total, serious adverse events",0,17.0,6,484,Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily
NCT01785472,E3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,"Total, other adverse events",2,17.0,66,484,Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily
NCT01876368,E1,LCZ696 200 mg,TRUE,LCZ696 200 mg,"Total, serious adverse events",0,17.0,0,188,Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
NCT01876368,E1,LCZ696 200 mg,TRUE,LCZ696 200 mg,"Total, other adverse events",2,17.0,7,188,Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
NCT01876368,E2,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,"Total, other adverse events",2,17.0,10,187,Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
NCT01876368,E2,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,"Total, serious adverse events",0,17.0,2,187,Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
NCT01975246,E1,Telmisartan and Amlodipine+HCTZ,TRUE,Telmisartan and Amlodipine+HCTZ,"Total, serious adverse events",0,,0,149,Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.
NCT01975246,E1,Telmisartan and Amlodipine+HCTZ,TRUE,Telmisartan and Amlodipine+HCTZ,"Total, other adverse events",5,MedDRA 17.0,36,149,Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.
NCT01975246,E2,Telmisartan+Amlodipine,TRUE,Telmisartan+Amlodipine,"Total, serious adverse events",0,,0,160,Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet
NCT01975246,E2,Telmisartan+Amlodipine,TRUE,Telmisartan+Amlodipine,"Total, other adverse events",5,MedDRA 17.0,14,160,Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet
